Filing Flows › Utah Medical Products (UTMD) › Takeover & LBO
Is Utah Medical Products (UTMD) a takeover target?
A leveraged buyout does not work for Utah Medical Products on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. Historically 4.3% of companies with its figures were bought within a year (0.86× the average). Latest signal (2026-09-24): Going-private statement (Schedule 13E-3).
Why a leveraged buyout does not fit
The buyout model needs Utah Medical Products' revenue, EBITDA, share count and share price; not all of them are on file, so it gives no buyout price.
What a takeover could cost
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium.
The odds, from history
Historically 4.3% of companies with its figures were bought within a year (0.86× the average). Its figures put it in decile 5 of 10 (10 = the most likely to be bought). The odds come from a model of every merger proxy, tender-offer response and going-private statement filed on EDGAR since 2011, set against each company's size, margins, debt, cash flow and growth the year before.
Rumors and deal signals
- 2026-09-24 · SC 13E3 · Going-private statement (Schedule 13E-3)
Utah Medical Products' latest quarter
Utah Medical Products, Q2 2026: revenue $8.5M (-14% year over year), operating margin 31.1%, net earnings $2.7M, operating cash flow $1.4M. The chart follows the revenue to costs, profit and cash.
Questions
Is Utah Medical Products being acquired?
The latest signal on file is from 2026-09-24: Going-private statement (Schedule 13E-3). A headline is not a deal; Filing Flows lists the news, 8-K filings and 13D filings about a sale.
Could private equity buy Utah Medical Products?
A leveraged buyout does not work for Utah Medical Products on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. The model gives no buyout price until they are.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.